SIGA Technologies, Inc. - 10-Q Summary (Period Ended June 30, 2009)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009. SIGA Technologies, Inc. is a bio-defense company focused on the discovery, development, and commercialization of products to defend against biological warfare agents (e.g., smallpox, Arenaviruses) and novel anti-infectives. The Company has no products currently approved for commercial sale and relies on government contracts, grants, and strategic alliances for funding. As of July 30, 2009, there were 37,554,753 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenues | $5,934,736 | $3,714,498 |
| Operating Expenses | $11,465,241 | $7,769,599 |
| Operating Loss | $(5,530,505) | $(4,055,101) |
| Net Loss | $(17,237,613) | $(3,999,040) |
| Net Loss Per Share (Basic/Diluted) | $(0.47) | $(0.12) |
| Cash and Cash Equivalents (End of Period) | $1,608,271 | $5,422,814 |
| Net Cash Used in Operating Activities | $(4,325,547) | $(3,999,597) |
| Net Cash Provided by Financing Activities | $3,804,086 | $2,756,589 |
| Total Liabilities | $21,570,658 | $7,242,701 |
| Stockholders' Equity | $(13,002,120) | $1,554,599 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 60% to $5.9 million, driven primarily by NIH contracts and grants (100% of total revenue). Specific increases included $1.3 million from large-scale manufacturing of ST-246 and $450,000 from an NIH contract for ST-246 development.
- Expense Increases: Operating expenses rose 48% to $11.5 million. Selling, General, and Administrative (SG&A) expenses increased 78% due to higher stock-based compensation ($575,000 increase) and legal/litigation support ($947,000 increase). R&D expenses increased 38% to $7.4 million, largely due to increased spending on the lead drug candidate ST-246.
- Non-Cash Losses: The Net Loss of $17.2 million was significantly impacted by a non-cash loss of $11.7 million related to the increase in the fair value of common stock warrants. This was necessitated by the adoption of EITF 07-05, which reclassified certain warrants as liabilities.
- Liquidity Position: Cash balances decreased by approximately $713,000 during the period. Total liabilities increased significantly to $21.6 million, primarily due to the reclassification of warrants as liabilities ($16.4 million total warrant liability).
Outlook, Risks, and Management Commentary
- Going Concern: Management believes existing cash, combined with proceeds from an investment commitment with MacAndrews & Forbes (M&F), continuing government grants, and anticipated new contracts, will support operations beyond the next twelve months. However, the Company has incurred cumulative net losses and has no commercial products.
- Financing: On April 30, 2009, the Company exercised a right to receive $1.5 million from M&F under a letter agreement. As of June 30, 2009, $6.5 million of the $8 million commitment remains available.
- Key Programs: The Company submitted a response to a BARDA Request for Proposal (RFP) for 1.7 million courses of a smallpox antiviral in May 2009 and was deemed technically acceptable. There is no assurance of an award.
- Legal Proceedings: PharmAthene, Inc. is suing SIGA regarding a license agreement for ST-246. SIGA filed a counterclaim. The Company cannot reasonably estimate a range of loss at this time.
- Compliance: The Company identified a non-compliance with HHS regulations regarding the submission of audited statements and expects to submit them by September 30, 2009. Management estimates potential enforcement costs will not be material.
Investor Verification Checklist
- Warrant Liability Valuation: Verify the assumptions used in the Black-Scholes model for the $16.4 million warrant liability, as changes in fair value significantly impact reported net loss.
- BARDA Contract Status: Monitor the outcome of the BARDA Smallpox RFP, as a contract award is critical for future revenue and liquidity.
- PharmAthene Litigation: Track the progress of the PharmAthene lawsuit, as an adverse ruling could require a license agreement or significant damages.
- Cash Burn Rate: Assess the sustainability of the current cash balance ($1.6 million) against the reported operating cash burn of $4.3 million over six months, considering the reliance on the M&F investment commitment.
- Government Funding Dependency: Confirm the status of NIH and other government grants, which comprised 100% of revenue for the period.